Robert J - School of Medicine
Robert J. Doolan, MD,
Denver Internal Medicine Group
360 South Garfield
Suite 550
Denver, CO 80209
Phone: 303-333-5456
Fax: 303-320-6910
Email: rdoolan@
Date of Birth: November 9, 1970
Graduate Education:
2002. Resident in Internal Medicine
University of Colorado Health Sciences Center
4200 East 9th Avenue
Denver, CO
1999. Doctor of Medicine
Wayne State University School of Medicine
540 East Canfield
Detroit, MI 48201
Undergraduate Education:
1992. B.S. Electrical Engineering
University of Michigan- Ann Arbor
Board Certification:
American Board of Internal Medicine
Initial certification 2002-2012
Recertification 2012-2022
Employment:
2003-Present Mountain View Clinical Research Inc, Principal and Sub Investigator Clinical Research,
Denver, CO
2002-2011 Select Specialty Hospital, Hospitalist
Denver, CO
2011-2013 Spalding Rehabilitaion Hospital, Hospitalist
Aurora, CO
2002-Present Denver Internal Medicine Group, Internal Medicine,
Denver, Co
2014-2015 Community Recovery, Colorado Medical Director
1995. Developmental Engineer, Lear Seating Corporation
Southfield, MI
1993. Test Engineer, Ford Motor Company
Dearborn, MI
Medical Boards:
2011-2013 Spalding Rehabilitation Hospital, Member at Large - Medical Executive Committee Aurora, CO
2011-2013 Spalding Rehabilitation Hospital, Chair Pharmacy and Therapeutics Committee Aurora, CO
2011-Present Key/SMPC Board Member Denver, CO
2012-2013 PHP Pioneer ACO Advisory Board Member Denver, CO
2014-Present PHP Education Committee SMPC representative
Lecture:
Lifting The Hex – The Role of Curanderos
ACP-ASIM Colorado Associates’ Scientific Meeting June 5, 2001
Memberships:
American College of Physicians
Colorado Medical Society
Denver Medical Society
Research Experience:
Sub- Investigator: A Phase III, Multi-Center, Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 vs.
Placebo in Subjects with Active Rheumatoid Arthritis on Background DMARDS
Who Have Failed Anti-TNF Therapy.
Sub- Investigator: A Phase III, Multi-Center, Randomized, Double-Blind
Placebo-Controlled Clinical Use Study to Evaluate the Safety and Tolerability of
BMS-188667 Administered Intravenously to Subjects with Active Rheumatoid
Arthritis (RA) With or Without Medical Co- Morbidities Receiving Disease
Modifying Anti- Rheumatic Drugs (DMARDS) and/or Biologics Approved for
RA.
Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel
Group, Multicenter Study to Determine the Efficacy and Safety of The Buprenorphine Transdermal Delivery System (BTDS) in Subjects with Moderate
To Severe Osteoarthritic Pain of the Hip or Knee.
Principal Investigator: A Phase III, Randomized, Three-Arm, Double-Blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination with Metformin Compared to Glimepiride in Combination with Metformin in subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Therapy Alone.
Principal Investigator: A 4-Week Randomized Double-Blind, Placebo-and Active Controlled, Parallel- group, Forced-titration Study Comparing Efficacy and Safety of Ascending Doses of CG5503 Prolonged Release Up to 233mg BID and Oxycodone Prolonged releases up to 20 mg BID to Placebo Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee. Phase IIB
Principal Investagator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise
Sub- Investigator: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Principal Investigator: A Multicenter, Randomized, Double –Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) In Combination with Thiasolidinedone Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiasolidinedone Therapy Alone
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Glyburide Alone
Principal Investigator: A Double Blind, Placebo Controlled, Randomized, Parallel Group Study of the On-Demand for Up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-Reported Abdominal Pain, Cramping, and Discomfort in an OTC-Like Study Population
Principal Investigator: A multi-center, randomized, open-label, active controlled,
Parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting.
Principal Investigator: Abbott Laboratories, “A Phase 3, Open-label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy and Safety of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects with Chronic Low Back Pain”
Principal Investigator: A Double Blind, Placebo Controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butyllbromide when Used and Based on a Patients Decision to Self Medicate for Up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-Reported Abdominal Pain or Discomfort Associated with Cramping in an OTC-Like Study Population
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Efficacy Study of Kadian NT ( Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to severe Chronic Pain Due to Osteoarthritis of the Hip or Knee
Principal Investigator: A Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain (LBP) or Osteoarthritis (OA) of the Hip or Knee
Principal Investigator: A Randomized, Double-Blind, Parallel-Group,
Multicenter, Multinational Study to Asses Glycemic Control with Rimonabant in
Comparison with Glimepiride over 1 Year in overweight/Obese Type 2 Diabetic
Patients Not Adequately Controlled with Metformin
Principal Investigator: A Long-Term, Randomized, Double-Blind, Parallel-
Group, Placebo-Controlled, Radiographic Study to Investigate the Safety and
Efficacy of Orally Administered SD-6010 In Subjects with Symptomatic
Osteoarthritis of the Knee
Principal Investigator: A 16-Week, Phase 1, Multicenter, Doulble-Blind,
Randomized, Naproxen, and Ibuprofen-controlled, Parallel-Group
Pharmacological Study to Assess the Effect of Naproxcinod (375 mg and 750 mg,
bid) and to Ibuprofen (600 mg, tid) on Arterial Blood Pressure as Measured by
Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients with Controlled
Essential Hypertension
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Phase 3Trial to Evaluate the Efficacy and Safety of Saxagliptin
(BMS-477118) as Monotherapy in Subjects with Type 2 Diabetes who Have
Inadequate Glycemic Control with Diet and Exercise
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo
Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin
(BMS-477118) In Combination with Thiazolidinedione Therapy Alone
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as
Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate HGlycemic
Controlwith Diet and Exercise
Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo
Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of
Dapaliflozin in Combination with Thiazolidinedione Therapy in Subjects with
Type 2 Diabetes Who Have Inadequate Glycemic Controlon Thiazolidinedione
Alone
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- new england school of medicine journal
- uci school of medicine careers
- uci school of medicine cost
- school of medicine uci
- harvard school of medicine cme
- nyu school of medicine registrar
- usc school of medicine greenville
- duke school of medicine stats
- harvard school of medicine requirements
- boston university school of medicine ranking
- perelman school of medicine upenn
- perelman school of medicine curriculum